Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 20, 2017

Primary Completion Date

July 12, 2018

Study Completion Date

July 12, 2018

Conditions
Left Sided Heart FailureLeft Ventricular Assist DeviceAnticoagulant TherapyGastro Intestinal BleedingThrombosis, LVADAnti-factor XaaPTTHeparin
Interventions
DEVICE

aPTT guided heparin management

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

DEVICE

Anti-factor Xa guided heparin management

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device

Trial Locations (1)

63110

Washington University in St Louis School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03143569 - Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial | Biotech Hunter | Biotech Hunter